ClinicalTrials.gg
Active, not recruitingNCT06763146IN-REALITYUpdated Nov 5, 2026

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice

An observational study in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Active, not recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Bayer · Observational

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Planned enrollment
11th of 17
1,200 · median 4,613
Started
2025
with 2 others
Observational
17 of 49
3 open now
Registered
43rd of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 11th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2025, is one of 17 observational ones, and was the 43rd registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 246 (57%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Read the detailed description

This is an observational study in which data already collected from people with chronic kidney disease (CKD) and Type 2 diabetes mellitus (T2D) are studied.

T2D is a condition in which glucose levels rise in the blood. It is one of the common causes of CKD and can lead to kidney failure. CKD is a long-term condition in which the kidneys' ability to work properly gradually decreases over time.

The study drug, finerenone, is already approved for doctors to prescribe to people with CKD and T2D. It blocks the activity of a protein involved in worsening kidney function.

People with CKD and T2D are already receiving treatment with finerenone based on the results of previous studies. These studies, however, did not include Indian participants.

To better understand the impact of finerenone on CKD and T2D, more knowledge is needed about how well it works in the Indian population.

The main purpose of the study is to learn more about how well finerenone works and how safe it is in Indian people with CKD and T2D. To do this, researchers will check:

  • participants' characteristics including age, sex, height and weight, and signs and symptoms of the disease
  • other conditions the participants may have along with CKD and T2D, additional medicines they have taken with finerenone, and different treatment patterns in Indian participants.

The different treatment pattern for finerenone includes:

  • specialty of the doctor who prescribed finerenone
  • the date of starting finerenone
  • whether participants were still taking finerenone at each follow-up visit
  • the date and reason for stopping finerenone early
  • the dose of finerenone the participants took and how often they took it
  • changes in the dosage either with a low dose or high dose compared with the previous firenone dose
  • after starting finerenone treatment: reseachers may ask to continue treatment with finerenone, or may suggest adding other treatments like SGLT2 inhibitors or potassium binders, or stop finerenone treatment
  • after stopping finerenone treatment: researchers may start other treatments, like SGLT2 inhibitors, RAAS inhibitors, or potassium binders or other therapy

Researchers will only look at the medical records from participants in India. Data collected will be from August 2022 to April 2024.

Researchers will track participants' data in India and will follow them until the end of the study period till Nov 2024, last visit date of the participant, the participant discontinues treatment with finerenone, death, kidney failure, or cancer of the kidney.

In this study, only available data from routine care in India are collected. No visits or tests are required as part of this study.

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus

Keywords

  • CKD
  • T2DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a diagnosis of CKD associated with T2D who are initiated on finerenone under routine clinical management.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients from India (Indian ethnicity) diagnosed with CKD and T2D prior to initiating finerenone (per the standard diagnostic criteria) and initiated on finerenone per approved label.
  • Patient was prescribed finerenone for the first time (drug naïve) for the management of CKD and T2D between 1st August 2022 and 30th April 2024.
  • Age 18 years or older at the time of finerenone initiation.

Exclusion criteria

Exclusion Criteria:

  • \<25 mL/min/1.73 m\^2
  • Serum potassium >5.0 mmol/L
  • Type 1 diabetes is recorded in the patient record
  • according to the local marketing authorization - Patient data will be excluded if below information is identified in the patient record at any point from index date to the end of observation period:
  • - Pregnancy.
  • - Lactation.
  • - Patient taking concomitant medications that are strong inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin and nefazodone).
  • - Addison's disease.
  • Patient was a part of an interventional clinical study between 1st August 2022 and 30th Nov 2024.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Finerenone (Kerendia, BAY948862)

    Patients with CKD and T2D from India who initiate on finerenone per approved label.

    Drug: Finerenone (Kerendia, BAY948862)

Interventions

  • Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.

06

What researchers measure

Primary outcomes

  1. Descriptive summary of specialty of prescribing physician

    Time frame: Retrospective data analysis from 2022 to 2024

  2. Date of finerenone initiation

    Time frame: Retrospective data analysis from 2022 to 2024

  3. If patient was receiving finerenone at the time of each follow-up visit (Yes/No)

    Time frame: Retrospective data analysis from 2022 to 2024

  4. Date of discontinuation of finerenone

    Time frame: Retrospective data analysis from 2022 to 2024

  5. Reason for discontinuation of finerenone

    Time frame: Retrospective data analysis from 2022 to 2024

  6. Dose of finerenone treatment

    Time frame: Retrospective data analysis from 2022 to 2024

  7. Frequency of finerenone treatment

    Time frame: Retrospective data analysis from 2022 to 2024

  8. The number of patients who initiated finerenone with a 10-mg dose and 20-mg dose

    Time frame: Retrospective data analysis from 2022 to 2024

  9. The proportion of patients who initiated finerenone with a 10-mg dose and have up-titrated to a 20-mg dose

    Time frame: Retrospective data analysis from 2022 to 2024

  10. The proportion of patients who initiated finerenone with a 20-mg dose and have down-titrated to a 10-mg dose

    Time frame: Retrospective data analysis from 2022 to 2024

  11. Actions taken after finerenone introduction

    Actions include continue treatment, addition of second therapy like SGLT2is, potassium binders, discontinue treatment

    Time frame: Retrospective data analysis from 2022 to 2024

  12. Actions taken after stop finerenone prescription

    Actions include initiate alternate therapy like Sodium-glucose transport protein-2 inhibitor (SGLT2is), RAASis or potassium binders, other

    Time frame: Retrospective data analysis from 2022 to 2024

Secondary outcomes

  1. UACR (mg/g) before and after initiating finerenone

    UACR: Urine Albumin to Creatinine Ratio

    Time frame: Retrospective data analysis from Aug 2022 to Apr 2024

  2. eGFR before and after initiating finerenone

    eGFR: Estimated glomerular filtration rate

    Time frame: Retrospective data analysis from Aug 2022 to Apr 2024

  3. Serum potassium (mmol/L) before and after initiating finerenone

    Time frame: Retrospective data analysis from Aug 2022 to Apr 2024

  4. Change in UACR after initiating finerenone vs month 1, month 4 and end of study

    Time frame: Retrospective data analysis from 2022 to 2024

  5. Change in serum potassium after initiating finerenone vs month 1, month 4 and end of study

    Time frame: Retrospective data analysis from Aug 2022 to Apr 2024

  6. Change in Serum creatinine/eGFR after initiating finerenone vs month 1, month 4 and end of study

    Time frame: Retrospective data analysis from Aug 2022 to Apr 2024

  7. Frequency of events like hospitalization and dialysis due to hyperkalemia

    Time frame: Retrospective data analysis from Aug 2022 to Apr 2024

07

Study locations

1 site
  • Many locations
    Many Locations, India
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Nov 2026, 14 months after the start.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 5, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 8, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Nov 30, 2026was Sep 2026
CompletionEst.
Nov 30, 2026was Sep 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Nov 30, 2026
moved 2 times, Oct 14, 2026 – Nov 5, 2026
Study completion
Sep 30, 2026→Nov 30, 2026
moved 2 times, Oct 14, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Primary completion Oct 31, 2026→Nov 30, 2026
    Study completion Oct 31, 2026→Nov 30, 2026
    + 1 other change: verification date
  2. Oct 14, 2026
    Primary completion Sep 30, 2026→Oct 31, 2026
    Study completion Sep 30, 2026→Oct 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06763146
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Sep 22, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion